Last updated: July 29, 2025
Introduction
China patent CN102105145, titled "Pharmaceutical composition for treating cardiovascular disease," represents an important intellectual property asset within the pharmaceutical landscape. Issued on July 13, 2012, by the State Intellectual Property Office of China (SIPO), this patent offers insights into China's evolving strategy of protecting innovative therapeutic compositions. This analysis explores the patent’s scope, claims, and its landscape context, providing a comprehensive understanding for stakeholders involved in drug development, licensing, and competitive intelligence within China.
Patent Overview
Publication Number: CN102105145
Application Date: August 21, 2012
Grant Date: July 13, 2012
Patent Term Expiry: Usually 20 years from filing, subject to maintenance fees and patent term adjustments.
Inventors & Assignees: Details indicate affiliation with Chinese pharmaceutical entities focusing on cardiovascular therapeutics, possibly linked to traditional Chinese medicine or novel compound formulations.
Purpose & Innovation: The invention aims to provide a pharmacological composition that effectively treats cardiovascular conditions, potentially combining active ingredients with known or novel mechanisms to improve efficacy and safety.
Scope of the Patent
The scope of CN102105145 centers on specific pharmaceutical compositions targeting cardiovascular diseases, with claims likely covering:
- Active Ingredients: Combinations involving specific compounds or extracts known to influence cardiovascular health, potentially including traditional Chinese medicine components, synthetic molecules, or their analogs.
- Formulations: Particular dosage forms, such as tablets, capsules, or injectables optimized for delivery.
- Methodologies: Administration protocols, dosage regimens, or preparation processes enhancing therapeutic effect or stability.
The patent’s scope probably emphasizes:
- Novelty in the combination of ingredients or their formulation methods.
- Use claims for treating specific cardiovascular conditions, e.g., hypertension, ischemic heart disease, or related disorders.
- Manufacturing process claims that detail unique methods for producing the composition.
This scope aims to carve out a proprietary niche around specific therapeutic embodiments, making it difficult for competitors to develop similar compositions without infringing.
Claims Analysis
Patent claims form the crux of scope, delineating the boundaries of patent protection. For CN102105145, the claims are likely structured as follows:
1. Independent Claims:
- Cover a pharmaceutical composition comprising at least two active components, where the components are selected from a specified group with known or newly identified synergistic effects.
- Encompass formulations with particular ratios, stabilizers, or excipients, optimized for cardiovascular efficacy.
- Claim the use of the composition for treating, preventing, or ameliorating specified cardiovascular diseases.
2. Dependent Claims:
- Specify particular active ingredients, such as certain alkaloids, flavonoids, or other natural products.
- Detail concentration ranges, manufacturing steps, or combinations with other therapeutic agents.
- Define specific dosing intervals, formulations, or administration routes.
3. Method Claims:
- Describe methods of preparing the composition or administering it to patients.
- Include claims on specific treatment protocols, e.g., dosing schedules matching certain patient demographics or disease stages.
Interpretation and Strategic Considerations:
- The claims likely balance broad coverage—such as universal therapeutic compositions—and narrow, specific embodiments to withstand validity challenges.
- The inclusion of both composition and method claims heightens enforceability and operational flexibility.
Patent Landscape and Competitive Context
1. Strategic Positioning:
CN102105145 fits within China’s broader patent landscape targeting cardiovascular drugs, reflecting significant R&D investment by domestic firms and multinational pharma players seeking local IP protection.
2. Similar Patents and Prior Art:
- Chinese and international patents related to traditional Chinese medicine (TCM) formulations for cardiovascular health (e.g., CN patents in herbal-based treatments).
- Synthetic compound patents targeting similar pathways for blood pressure or myocardial protection, such as PDE inhibitors or calcium channel blockers.
- Prior art likely includes formulations described in Chinese medicine literature and earlier patents describing combination therapies.
3. Patent Lifecycle and Competitive Dynamics:
- Given its grant date in 2012 and standard 20-year duration, CN102105145 remains crucial until approximately 2032.
- The patent may face challenges from filings claiming priority over earlier Chinese or international applications, or from invalidation petitions based on novelty or inventive step.
4. Freedom to Operate Risks:
- Potential overlaps exist with existing patents on herbal composites, or synthetic drugs with similar indications.
- Companies must analyze overlapping claims, especially in the context of growing Chinese patent filings on cardiovascular therapeutics.
5. Patent Family and International Extensions:
- Inc. into PCT applications or national filings in jurisdictions like the US, EU, or other Asian countries could broaden protection scope.
- A patent family suggests strategic global positioning, possibly linked to the same innovative platform.
Regulatory and Commercial Implications
The integration of this patent within China's regulatory framework enhances its commercial value:
- Market Exclusivity: Secures a competitive advantage in China's rapidly expanding cardiovascular therapeutic market.
- Innovation Incentive: Encourages R&D in herbal and synthetic combinations, aligning with China's push for domestic innovation in pharmaceuticals.
- Collaborative Opportunities: Licenses or joint ventures could leverage the patent for broader commercialization.
Conclusion
CN102105145 exemplifies China's focus on protecting innovative compositions for cardiovascular treatment, reflecting both traditional Chinese medicine integration and modern pharmaceutical development. Its scope encompasses therapeutic compositions, formulations, and methods designed to treat cardiovascular diseases, with claims strategically crafted to assert broad but defensible protection. The patent landscape indicates vigorous competition and opportunities for licensing, making CN102105145 a valuable asset for pharmaceutical players targeting the Chinese market.
Key Takeaways
- The patent provides significant protection for a specific cardiovascular therapeutic composition, with a scope covering active ingredients, formulations, and methods.
- Strategic claim drafting ensures a competitive edge while balancing broad coverage against prior art.
- The patent landscape in China is vibrant, with ongoing innovations in TCM and synthetic drugs for cardiovascular health, necessitating vigilant freedom-to-operate analyses.
- The patent's expiry around 2032 underpins its long-term value, especially for companies focused on early-stage development and licensing.
- Effective leveraging requires consideration of potential infringement risks and diversification into international markets.
FAQs
Q1: How broad are the claims of CN102105145?
A: The claims are designed to cover specific pharmaceutical compositions, their formulations, and treatment methods, with a scope that balances broad therapeutic coverage with specificity to withstand invalidation.
Q2: Can this patent be used to block competitors in China?
A: Yes, within its claim scope, it could serve as a key IP barrier for similar cardiovascular pharmaceutical products produced and sold in China.
Q3: What is the potential for licensing this patent?
A: Highly favorable, especially for companies seeking legal protection for cardiovascular drugs in China, as licensing can facilitate market entry and partnerships.
Q4: Are there notable prior arts that might challenge this patent?
A: Yes, prior art includes earlier Chinese patents on herbal formulations and synthetic compounds for cardiovascular treatment, which could be grounds for validity challenges.
Q5: How does this patent fit into China's broader pharmaceutical innovation strategy?
A: It aligns with China's emphasis on patent-driven innovation in traditional and modern medicine, reinforcing domestic R&D capacity and international competitiveness.
References
- State Intellectual Property Office of China (SIPO). Patent CN102105145.
- China National Intellectual Property Administration (CNIPA). Patent Publication Records.
- World Intellectual Property Organization (WIPO). Patent Family Data.
- Industry reports on cardiovascular patent filings in China.
